1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

23 Mar 2021
Admin
News Article

Wuxi Biologics Buys Manufacturing Facilities From Pfizer China

Wuxi Biologics, A Global Company With Leading Open-Access Biologics Technology Platforms, Has Announced That It Has Entered Into An Equity Agreement With Pfizer China To Acquire Its State-Of-The-Art Biologics Manufacturing Facilities As Well As Its Labor Force In Hangzhou, China.The Transaction Is Expected To Close In The First Half Of 2021, Which Will Immediately Boost The Commercial Drug Substance (Ds) And Drug Product (Dp) Capacities For Wuxi Biologics To Address Surging Manufacturing Demands.The State-Of-The-Art 50,000 M2 Facilities, Gmp Operational Since 2018, Includes Ds Capacities Equipped With 2X2000L Single-Use Bioreactors Expandable To 4X2000L (Mfg20) And Dp Capacities Of Vial Filling (Dp9) And Pre-Filled Syringe (Dp10).Leveraging The Facilities' Experienced Workforce And Wuxi Biologics' Extensive Expertise In Manufacturing And Regulation, The Production Is Expected To Commence Shortly After The Deal Closure. Dr. Chris Chen, Ceo Of Wuxi Biologics, Commented, "We Are Pleased To Work With Pfizer And Add The New Hangzhou Biologics Manufacturing Facilities To Our Global Network To Address The Surging Manufacturing Demands For Late-Stage And Commercial Projects Due To The Success Of Our Win-The-Molecule Strategy. Globally Ds And Especially Dp Capacities Are In Urgent Need Now. The Acquisition Will Allow Us To Better Enable Our Global Partners To Develop And Manufacture Premier-Quality Biologics To Benefit Patients Around The World."

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!